Lifecore Biomedical Inc., a fully-owned subsidiary of Landec Corporation, has announced the receipt by Heron Therapeutics, one of Lifecore’s customers, of U.S. Food and Drug Administration (FDA) approval for its Zynrelef (formerly known as HTX-011) candidate on May 13, 2021, for which for Lifecore provides CDMO support.   Heron received FDA approval for Zynrelef (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsu...